← Back to Search

Study group for Breast Cancer

N/A
Recruiting
Led By Linda A Koehler, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3, 6, 9, and 12 months
Awards & highlights

Summary

Breast cancer is the second most common cancer in women. One in five women who have been treated for breast cancer develop lymphedema. Lymphedema is a very common result of breast cancer and its treatment. Lymphedema is the build-up of fluid in tissues, which results in tissue swelling. The lymph system is a network of lymph vessels, tissues, and organs that carry extra fluid from your cells/tissues throughout the body. If this lymph fluid is not able to flow in the body how it should, there will be swelling which can lead to lymphedema. It can be classified into stages 0 to 3 depending on the severity of the condition. Stages 0 and 1 are reversible, and through early diagnosis and treatment, the recovery to the normal volume and normal skin status of arms can be possible. On the other hand, stage 2 or higher is irreversible, and tissue fibrosis progresses and cannot return to normal skin; therefore, it is important to detect early and start treatment. This is an observational longitudinal study. Potential participants will be recruited for follow-up after breast cancer surgery. Only patients who fit the inclusion criteria will be considered for participation in the study and contacted by the healthcare provider. Standard of care will be used to guide any treatment needed by participants while they are part of the study.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3, 6, 9, and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 6, 9, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Bilateral upper extremity girth circumference measurements
Bilateral upper extremity shoulder goniometric range of motion measurements
Disabilities
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Study groupExperimental Treatment1 Intervention
breast cancer patients 1-12 months post surgery

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,413 Previous Clinical Trials
1,561,333 Total Patients Enrolled
7 Trials studying Breast Cancer
1,705 Patients Enrolled for Breast Cancer
Linda A Koehler, PhDPrincipal InvestigatorUniversity of Minnesota
~53 spots leftby Sep 2025